Previous 10 | Next 10 |
Launched development program for a DPX-based vaccine candidate against COVID-19 Reported updated Phase 2 data from DeCidE1 study in advanced ovarian cancer; These encouraging results support DPX-Survivac being amongst the first in vivo T cell therapy to demonstrate meaningful cli...
Plus Therapeutics. (NASDAQ: PSTV ) +63% in-licenses novel oncology candidates. More news on: Plus Therapeutics, Inc., Bellerophon Therapeutics, Inc., Owens & Minor, Inc., Stocks on the move, , Read more ...
IMV (NASDAQ: IMV ) provides updates on the development of DPX-COVID-19, a vaccine candidate against coronavirus. More news on: IMV Inc., Healthcare stocks news, Stocks on the move, Read more ...
IMV Inc. (Nasdaq: IMV) (TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the Company’s business and clinical o...
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold a conference call and webcast on Wednesday, March 31, 2020 at 8:00 a.m. Eastern ...
Moderna ( MRNA -15.9% ) slumps on more than double normal volume on the heels of comments today from FDA Commissioner Stephen Hahn (during the Coronavirus Task Force briefing) that approval of a COVID-19 vaccine is at least a year away which is consistent with health authorities' expecta...
Biomerica (NASDAQ: BMRA ) +133% on advancement of rapid coronavirus test. More news on: Biomerica, Inc., IMV Inc., Vaxart, Inc., Stocks on the move, , Read more ...
Capitalizing on its coronavirus vaccine -stoked rally, IMV (NASDAQ: IMV ) has inked an agreement with Piper Sandler for the at-the-market sale of up to $30M of its common stock. More news on: IMV Inc., Healthcare stocks news, Stocks on the move, , Read more ...
IMV Inc. (TSX: IMV; NASDAQ: IMV) (the "Company" or “IMV”), a clinical-stage biopharmaceutical company, today announced that it has entered into an equity distribution agreement, dated March 18, 2020, with Piper Sandler & Co. ("Piper Sandler") as agent, pursuant to which the ...
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today announced that it is advancing the clinical development of a DPX-based vaccine candidate against COVID-19. Vaccines against infectious disease have been a c...
News, Short Squeeze, Breakout and More Instantly...
GAAP Net Income of $8.3 million or $0.25 per diluted share Non-GAAP Net Income of $11.0 million or $0.33 per diluted share Declares Third Consecutive Quarterly Dividend Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, to...
IMV Inc. (the “ Company ” or “ IMV ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced tha...
Horizon Technology Finance Announces First Quarter 2023 Financial Results PR Newswire - First Quarter 2023 Net Investment Income per Share of $0.46 ; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to ...